Antacids

Class: Antacids and Adsorbents
ATC Class: A02A
VA Class: GA209
CAS Number: 53547-27-6
Brands: Alamag, Alamag Plus, Alka-Mints, Alka-Seltzer Gold Effervescent Antacid, Almacone, Almacone II Hi-Potency, ALternaGEL, Alu-Cap, Alu-Tab, Amphojel, Basaljel, Chooz, Citrocarbonate Granules, Di-Gel, Gaviscon, Gaviscon Extra Strength, Genaton, Kudrox, Lowsium, Lowsium Plus, Maalox, Maalox Advanced Regular Strength, Maalox Advanced Maximum Strength, Maalox Antacid/Anti-Gas Maximum Strength, Maalox Max Quick Dissolve Chewables Antacid/Antigas Maximum Strength, Maalox Quick Dissolve Chewables, Maalox Quick Dissolve Chewables Maximum Strength, Maalox TC, Mag-Al, Mag-Al Plus, Mag-Al XS, Mag-Ox, Marblen, Milk of Magnesia, Mygel, Mygel II, Mylanta, Mylanta Children’s Upset Stomach Relief, Mylanta Fast-Acting, Mylanta Fast-Acting Double Strength, Mylanta Fast-Acting Maximum Strength, Mylanta Supreme Fast Acting, Pepcid Complete, Phillips’ Milk of Magnesia, Riopan Plus, Riopan Plus Double Strength, Rolaids Antacid, Rulox, Tempo, Titralac Extra Strength, Titralac Plus, Titralac Regular, Tums Antacid/Calcium Supplement, Tums E-X Antacid/Calcium Supplement, Tums Ultra Antacid/Calcium Supplement, Uro-Mag

Introduction

Inorganic salts that partially neutralize gastric hydrochloric acid.b

Uses for Antacids

Peptic Ulcers

Adjunct to other drugs (e.g., anti-infectives, histamine H2-receptor antagonists, proton-pump inhibitors) for the relief of peptic ulcer pain and to promote the healing of peptic ulcers.b

Because of the inconvenience of the regimens needed to promote ulcer healing, high recurrence rate, ineffectiveness in eradicating Helicobacter pylori, palatability issues, and adverse effects, antacids rarely are used alone any longer for the treatment of peptic ulcer disease.200 220 234 238 242 243 252 b d Instead, antacids currently are used principally as an adjunct to other antiulcer regimens for as-needed (prn) relief of peptic ulcer pain.b d

Acid Indigestion

Self-medication for the relief of acid indigestion (dyspepsia), heartburn, and sour stomach and/or bloating (commonly referred as gas).267 a

Gastroesophageal Reflux Disease (GERD)

Self-medication for the relief of mild forms of GERD (e.g., symptoms induced by a heartburn-inducing meal).265 a e

Antacids generally provide more rapid but less prolonged relief of GERD symptoms compared with histamine H2-receptor antagonists, and combined therapy generally is more effective than either class of drugs alone.e

Consult a clinician if symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).265 e

Other agents (e.g., histamine H2-receptor antagonists, proton-pump inhibitors) preferred by American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) for management of more severe forms of GERD.265 b e

Have been used for self-medication for the relief of breakthrough symptoms in patients receiving proton-pump inhibitors.e

Hyperphosphatemia

Aluminum-containing antacids (except aluminum phosphate): Management of hyperphosphatemia or prevention of recurrent phosphatic renal calculi (in conjunction with a low phosphate diet).a b

Aluminum carbonate generally preferred to aluminum hydroxide for this use.b

Calcium Replacement

Calcium carbonate is used for calcium supplementation.b

Stress Ulceration and GI Bleeding

Has been used for prevention of stress ulceration and GI bleeding.b

Gastric Acid Aspiration

Has been used for prevention of gastric acid aspiration in patients undergoing cesarean section or emergency surgery;b generally has been replaced by histamine H2-receptor antagonist or citrate solution.c

Antacids Dosage and Administration

Administration

Oral Administration

Administer orally.b

Oral suspensions more rapidly and effectively solubilized than powders or tablets; reserve oral tablets for chronic use in patients who refuse oral suspensions because of inconvenience or unpalatable taste.b Rapidly disintegrating tablets may be a suitable alternative in some patients.b

Chew tablets, including rapidly dissolving tablets, thoroughly before swallowing.b

Dosage

Available as various inorganic salts (e.g., aluminum carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium bicarbonate); dosage is expressed in terms of mEq of acid neutralizing capacity.b

Dose and frequency of administration depend on the acid secretory rate of the stomach, gastric emptying time, and the disorder being treated.b

Adults

Peptic Ulcers

For peptic ulcer disease, dosages of antacids are empirical and various antacid dosages have been used.b

Adjunctive Therapy
Oral

For supplemental ulcer pain relief, 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis.f

Treatment
Oral

Other therapies currently are preferred for treatment of active peptic ulcers.200 220 234 238 242 243 252 b d (See Peptic Ulcers under Uses.)

If antacids are used for the treatment of peptic ulcers, usual high-dose regimens for ulcer healing employ 80–160 mEq acid neutralizing capacity, given 1 and 3 hours after meals and at bedtime.f

Additional doses of antacids may be administered to relieve ulcer pain that occurs between regularly scheduled doses.b

In patients with duodenal ulcers, antacids usually are given for 4–6 weeks.b If symptoms of duodenal ulcer recur, antacids can be administered 1 and 3 hours after meals and at bedtime for 1 week and, if pain is relieved, less frequently for an additional 1–2 weeks.b

In patients with gastric ulcers, antacids are administered until healing is complete.b

Gastroesophageal Reflux Disease (GERD)

For GERD, dosages of antacids are empirical and various antacid dosages have been used.b d f

Oral

For relief of heartburn, one recommended regimen employs 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis intially.d f If necessary, dosage can be titrated to a regularly scheduled basis such as 40–80 mEq acid neutralizing capacity given after meals and at bedtime.d f

Hyperphosphatemia
Oral

In conjunction with dietary phosphate restriction in the management of hyperphosphatemia, 30–40 mL of aluminum hydroxide or aluminum carbonate suspension is administered 3 or 4 times daily.

Calcium Replacement
Oral

For calcium replacement dosage with calcium carbonate, see Dosage in Calcium Salts 40:12.

Stress Ulceration and GI Bleeding
Oral

In the management of stress ulceration and GI bleeding, antacids are usually administered every hour, and the antacid dosage should be titrated to maintain the nasogastric aspirate above pH 3.5.b

For severe symptoms, antacid suspensions may be diluted with water or milk and given by continuous intragastric infusion.b

Gastric Acid Aspiration
Oral

To reduce the risk of anesthesia-induced gastric acid aspiration, an antacid suspension has been given 30 minutes before anesthesia.

Prescribing Limits

Adults

GERD
Oral

Do not exceed 500–600 mEq acid neutralizing capacity daily or regularly scheduled (versus as-needed; prn) therapy for longer than 2 weeks continuously.d f

Sodium Bicarbonate

Maximum daily dosage of sodium or bicarbonate is 200 mEq in patients <60 years of age and 100 mEq in patients >60 years of age.b Contraindicated for prolonged therapy because it may cause metabolic alkalosis or sodium overload.b

Cautions for Antacids

Contraindications

  • Sodium bicarbonate is contraindicated and use of other sodium-containing antacids should be restricted in patients on low-sodium diets and in those with CHF, renal failure, edema, or cirrhosis.b

Warnings/Precautions

Warnings

Phenylketonuria

Some antacids may contain aspartame (e.g., NutraSweet), which is metabolized in the GI tract to phenylalanine following oral administration.b

Sensitivity Reactions

Tartrazine Sensitivity

Some antacid formulations contain the dye tartrazine (FD&C yellow No. 5), which may cause allergic-type reactions (bronchial asthma in susceptible individuals) in certain susceptible individuals (e.g., patients who are sensitive to aspirin).b

General Precautions

Aluminum Antacids

Risk of hypophosphatemia with prolonged administration or large doses, particularly in patients with inadequate dietary intake of phosphorus.b

Monitor serum phosphate concentrations at monthly or bimonthly intervals in patients on maintenance hemodialysis who are receiving chronic aluminum antacid therapy.b

Calcium Carbonate

May cause gastric hypersecretion and acid rebound.b

May cause the milk-alkali syndrome (characterized by hypercalcemia, metabolic alkalosis and, rarely, renal insufficiency).b

Monitor serum calcium concentrations weekly and whenever manifestations of hypercalcemia occur in patients receiving large doses of calcium carbonate.b

Magnesium Antacids

Commonly cause a laxative effect, and frequent administration of these antacids alone often cannot be tolerated; repeated doses cause diarrhea which may cause fluid and electrolyte imbalances.b

Sodium Bicarbonate

May cause metabolic alkalosis when given in large doses.b

Medication Errors

Serious medication errors have been reported to FDA in which consumers used Maalox Total Relief (bismuth subsalicylate) when they intended to use traditional Maalox liquid antacid products containing aluminum hydroxide, magnesium hydroxide, and simethicone (e.g., Maalox Advanced Regular Strength, Maalox Advanced Maximum Strength).266 267 268 Because of the potential for serious adverse effects associated with accidental use of bismuth subsalicylate (which is chemically related to aspirin), the manufacturer of Maalox Total Relief initially agreed to change the trade name of the product to one that did not include “Maalox”; however, the manufacturer instead discontinued the bismuth subsalicylate preparation in the summer of 2010.267 269

Specific Populations

Renal Impairment

Aluminum Antacids: Long-term administration in patients with renal failure or chronic renal failure may result in hyperaluminemia since small amounts of aluminum are absorbed from the GI tract and excretion of aluminum is decreased in patients with renal failure.b Aluminum accumulation in the CNS may be the cause of dialysis encephalopathy, while aluminum accumulation in the bones may result in or worsen dialysis osteomalacia.b

Calcium Carbonate: Patients with renal impairment or dehydration and electrolyte imbalance are predisposed to developing the milk-alkali syndrome.b Hypercalcemia risk in chronic hemodialysis patients.b

Magnesium Antacids: In patients with severe renal impairment, hypermagnesemia characterized by hypotension, nausea, vomiting, ECG changes, respiratory or mental depression, and coma.b Do not administer in patients with renal failure, and antacids containing more than 50 mEq of magnesium in the recommended daily dosage should be used cautiously and only under the supervision of a clinician who should monitor electrolytes in patients with renal disease.b

Sodium Bicarbonate: May cause metabolic alkalosis in patients with renal insufficiency.b

Common Adverse Effects

With prolonged administration, constipation (e.g., aluminum salts, calcium carbonate), diarrhea (e.g., magnesium salts), gastric distension/flatulence (e.g., sodium bicarbonate), and gastric hypersecretion/acid rebound (e.g., calcium carbonate).b

Interactions for Antacids

All antacids potentially may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs by changing GI transit time or by binding or chelating the drug.b In vitro studies indicate that magnesium hydroxide or trisilicate has the greatest potential for drug binding and aluminum hydroxide and calcium carbonate are intermediate.b

Specific Drugs and Food

Drug

Interaction

Comments

Aspirin

Pharmacokinetic (increased absorption of buffered or enteric-coated aspirin or decreased blood salicylate concentrations) interactionsb

Chlordiazepoxide

Possible decreased chlordiazepoxide absorption with aluminum hydroxide and magnesium preparationsb

Diazepam

Possible increased diazepam absorption with aluminum hydroxideb

Digoxin

Possible decreased digoxin absorptionb

Space doses of the drugs as far apart as possibleb

Indomethacin

Possible decreased indomethacin absorptionb

Space doses of the drugs as far apart as possibleb

Iron salts

Possible decreased absorption of iron saltsb

Space doses of the drugs as far apart as possibleb

Isoniazid

Possible decreased isoniazid absorption with aluminum hydroxideb

Administer isoniazid at least 1 hour before aluminum-containing antacidsb

Milk or other calcium-containing foods

Possible milk-alkali syndrome with chronic administration of bicarbonate and milk or calciumb

Naproxen

Possible increased naproxen absorption with sodium bicarbonateb

Possible decreased naproxen absorption with magnesium oxide or aluminum hydroxideb

Pseudoephedrine

Possible increased pseudoephedrine absorption with aluminum hydroxideb

Tetracyclines

Possible decreased tetracycline absorptionb

Allow 1–2 hours to elapse between doses of antacids and tetracyclinesb

Actions

  • Mechanism of action in the treatment of peptic ulcers is based on ability of antacids to react with hydrochloric acid and thus increase gastric pH.b

  • With usual doses, antacids generally do not increase and maintain gastric pH above 4–5.b

  • Antacids, in decreasing order of their ability to neutralize a given amount of acid, are calcium carbonate, sodium bicarbonate, magnesium salts, and aluminum salts.b

  • Aluminum-containing antacids (except aluminum phosphate) combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminum phosphate which is excreted in the feces.b If phosphate intake is limited and renal function is normal, aluminum antacids (except aluminum phosphate) decrease phosphate absorption and hypophosphatemia and hypophosphaturia occur.b

  • Magnesium-containing antacids have a laxative action.b

Advice to Patients

  • Advise patients to consult a clinician if ulcer pain worsens or is not relieved after the first week of therapy.b

  • Importance of consulting a clinician if GERD symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).265 d

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.b

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.b

  • Importance of informing patients of other important precautionary information.b (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Aluminum Carbonate, Basic

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg

Basaljel

Wyeth

Tablets

equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg

Basaljel (scored)

Wyeth

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Aluminum Hydroxide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

475 mg

Alu-Cap

3M

Suspension

320 mg/5 mL*

Aluminum Hydroxide Suspension

Amphojel

Wyeth

600 mg/5 mL

ALternaGEL

J&J-Merck

Tablets

300 mg

Amphojel

Wyeth

Tablets, film-coated

600 mg

Alu-Tab

3M

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Calcium Carbonate, Precipitated (Precipitated Chalk)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Oral

Pieces, chewing gum

500 mg

Chooz

Insight

Suspension

400 mg/5 mL

Mylanta Children’s Upset Stomach Relief

J&J-Merck

1.25 g/5 mL*

Calcium Carbonate Suspension

Tablets

1.25 g*

Calcium Carbonate Tablets (scored)

Tablets, chewable

400 mg

Mylanta Children’s Upset Stomach Relief

J&J-Merck

420 mg

Titralac Regular

3M

500 mg

Tums Antacid/Calcium Supplement

GlaxoSmithKline

650 mg*

Calcium Carbonate Chewable Tablets

750 mg

Titralac Extra Strength

3M

Tums E-X Antacid/Calcium Supplement

GlaxoSmithKline

850 mg

Alka-Mints

Bayer

1 g

Tums Ultra Antacid/Calcium Supplement

GlaxoSmithKline

Tablets, chewable, rapidly disintegrating

600 mg

Maalox Quick Dissolve Chewables

Novartis

1 g

Maalox Quick Dissolve Chewables Maximum Strength

Novartis

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Dihydroxyaluminum Sodium Carbonate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Magaldrate (Aluminum Magnesium Hydroxide)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

540 mg/5 mL

Lowsium

Rugby

Magaldrate Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

540 mg/5 mL with Simethicone 40 mg/5 mL

Lowsium Plus

Rugby

Riopan Plus

Wyeth

1080 mg/5 mL with Simethicone 40 mg/5mL

Riopan Plus Double Strength

Wyeth

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Magnesium Carbonate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Magnesium Hydroxide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Oral

Suspension

400 mg/5 mL*

Milk of Magnesia

Phillips’ Milk of Magnesia

Bayer

800 mg/5 mL

Phillips’ Milk of Magnesia Concentrate

Bayer

1.2 g/5 mL*

Milk of Magnesia Concentrate

Roxane

Tablets

300 mg*

Phillips’ Milk of Magnesia

Bayer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Magnesium Oxide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Oral

Capsules

140 mg

Uro-Mag

Blaine

Tablets

400 mg*

Magnesium Oxide Tablets

Mag-Ox 400

Blaine

420 mg*

Magnesium Oxide Tablets

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Magnesium Trisilicate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Sodium Bicarbonate (Baking Soda)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Oral

For solution

0.78 g/3.9 g

Citrocarbonate Granules

Lee

Tablets

325 mg*

Sodium Bicarbonate Tablets

650 mg*

Sodium Bicarbonate Tablets

Aluminum Hydroxide and Magnesium Carbonate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

Aluminum Hydroxide 31.7 mg/5 mL and Magnesium Carbonate 119.3 mg/5 mL

Gaviscon Liquid

GlaxoSmithKline

Genaton Liquid

Teva

Aluminum Hydroxide 254 mg/5 mL and Magnesium Carbonate 237.5 mg/5 mL

Gaviscon Extra Strength

GlaxoSmithKline

Tablets, chewable

Aluminum Hydroxide 160 mg and Magnesium Carbonate 105 mg

Gaviscon Extra Strength

GlaxoSmithKline

Aluminum Hydroxide and Magnesium Hydroxide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

Aluminum Hydroxide 200 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL

Mag-Al

Pharmaceutical Associates

Aluminum Hydroxide 225 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL

Alamag

Teva, URL

Maalox

Novartis

Rulox

Rugby

Aluminum Hydroxide 600 mg/5 mL and Magnesium Hydroxide 300 mg/5 mL

Maalox TC

Novartis

Tablets, chewable

Aluminum Hydroxide 200 mg and Magnesium Hydroxide 200 mg

Rulox #1

Rugby

Aluminum Hydroxide and Magnesium Hydroxide Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

Aluminum Hydroxide 200 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 20 mg/5 mL

Almacone

Rugby

Di-Gel

Schering-Plough

Maalox Advanced Regular Strength

Novartis

Mag-Al Plus

Pharmaceutical Associates

Mygel

Sandoz

Mylanta Fast-Acting

J&J-Merck

Aluminum Hydroxide 225 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 25 mg/5 mL

Alamag Plus

Teva

Aluminum Hydroxide 400 mg/5 mL, Magnesium Hydroxide 400 mg/5 mL, and Simethicone 40 mg/5 mL

Almacone II Hi-Potency

Rugby

Antacid Double Strength

Teva

Maalox Advanced Maximum Strength

Novartis

Mag-Al XS

Pharmaceutical Associates

Mygel II

Sandoz

Mylanta Fast-Acting Double Strength

J&J-Merck

Aluminum Hydroxide 500 mg/5 mL, Magnesium Hydroxide 450 mg/5 mL, and Simethicone 40 mg/5 mL

Kudrox

Schwarz

Maalox Antacid/Anti-Gas Maximum Strength

Novartis

Tablets, chewable

Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg

Almacone

Rugby

Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 25 mg

Tempo

Blairex

Aluminum Hydroxide and Magnesium Trisilicate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, chewable

Aluminum Hydroxide 80 mg and Magnesium Trisilicate 20 mg

Gaviscon

GlaxoSmithKline

Genaton

Teva

Calcium Carbonate and Magnesium Carbonate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

Calcium Carbonate 520 mg/5 mL and Magnesium Carbonate 400 mg/5 mL

Marblen

Fleming

Calcium Carbonate and Magnesium Hydroxide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

Calcium Carbonate 400 mg/5 mL and Magnesium Hydroxide 135 mg/5 mL

Mylanta Supreme Fast Acting

J&J-Merck

Tablets

Calcium Carbonate 550 mg and Magnesium Hydroxide 125 mg

Mylanta Gelcaps

J&J-Merck

Tablets, chewable

Calcium Carbonate 350 mg and Magnesium Hydroxide 150 mg

Mylanta Fast-Acting

J&J-Merck

Calcium Carbonate 500 mg and Magnesium Hydroxide 110 mg

Rolaids Antacid

Pfizer

Calcium Carbonate 700 mg and Magnesium Hydroxide 300 mg

Mylanta Fast-Acting Maximum Strength

J&J-Merck

Calcium Carbonate and Magnesium Hydroxide Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

Calcium Carbonate 280 mg, Magnesium Hydroxide 128 mg, and Simethicone 20 mg

Di-Gel

Schering-Plough

Tablets, chewable

Calicum Carbonate 800 mg, Magnesium Hydroxide 165 mg, and Famotidine 10 mg

Pepcid Complete

J&J-Merck

Other Calcium Carbonate Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

420 mg with Simethicone 21 mg

Titralac Plus

3M

Tablets, chewable, rapidly disintegrating

1 g with Simethicone 60 mg

Maalox Max Quick Dissolve Chewables Antacid/Antigas Maximum Strength

Novartis

Potassium Bicarbonate and Sodium Bicarbonate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, for solution

Potassium Bicarbonate 312 mg and Sodium Bicarbonate 958 mg

Alka-Seltzer Gold Effervescent Antacid

Bayer

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Calcium Carbonate 1250MG/5ML Suspension (ROXANE): 500/$20.99 or 1500/$40.97

Caltrate 600 1500MG Tablets (PFIZER CONSUMER HEALTHCARE): 60/$15.99 or 120/$21.97

Mag-Ox 400 400MG Tablets (HEALTH CARE PRODUCTS): 120/$23.99 or 240/$37.97

Mag-Oxide 400MG Tablets (RISING PHARMACEUTICALS): 30/$12.99 or 90/$15.97

Oyst-Cal 500MG Tablets (IVAX PHARMACEUTICALS): 120/$13.99 or 240/$16.97

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions February 1, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

200. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. [IDIS 307044] [PubMed 8428432]

201. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect Dis. 1992; 15:386-91. [IDIS 301064] [PubMed 1520782]

202. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. [PubMed 8449566]

203. Bayerdörffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. [PubMed 8341987]

204. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.

205. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl. 1993; 196:12-6. [PubMed 8341986]

206. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. [PubMed 8341989]

207. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. [PubMed 8341990]

208. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. [PubMed 8450375]

209. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. [PubMed 1891021]

210. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. [PubMed 1891020]

211. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993; 341:1359-62. [PubMed 8098787]

212. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. [PubMed 1770552]

213. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. [PubMed 2059685]

214. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. [PubMed 1770545]

215. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. [PubMed 8449573]

216. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.

217. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.

218. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5. [IDIS 267578] [PubMed 1971318]

219. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. [IDIS 313340] [PubMed 8470623]

220. Reviewers’ comments (personal observations) on Helicobacter pylori. Clarithromycin 8:12.12.

221. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.

222. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. [IDIS 320468] [PubMed 8406147]

223. Anon. Drugs for treatment of peptic ulcer. Med Lett Drugs Ther. 1994; 36:65-7. [PubMed 7912812]

224. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol Suppl. 1994; 201:49-54. [PubMed 8047824]

225. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994; 201:16-23. [PubMed 8047818]

226. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. [IDIS 329264] [PubMed 8172146]

227. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. [IDIS 324883] [PubMed 8307443]

228. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9. [IDIS 332306] [PubMed 8007082]

229. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994; 154:721-7.

230. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. [IDIS 324011] [PubMed 8273795]

231. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA. 1994; 271:808-9. [PubMed 8114221]

232. Feldman M. The acid test. Making clinical sense of the consensus conference on Helicobacter pylori. JAMA. 1994; 272:70-1. [PubMed 8007084]

233. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. [PubMed 8741237]

234. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. [IDIS 361115] [PubMed 8594244]

235. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Clin Infect Dis. 1992; 15(Suppl 1):S268-73.

236. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87:1716-27. [IDIS 307322] [PubMed 1449132]

237. Glassman MS. Helicobacter pylori infection in children. A clinical overview. Clin Pediatr (Phila). 1992; 31:481-7. [IDIS 300639] [PubMed 1643767]

238. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8. [IDIS 279263] [PubMed 2005942]

239. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. [IDIS 312865] [PubMed 8491391]

240. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89:1785-8. [IDIS 336721] [PubMed 7942667]

241. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. [IDIS 336723] [PubMed 7942669]

242. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. [IDIS 354448] [PubMed 7666920]

243. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. [PubMed 8862962]

244. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.

245. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. [PubMed 9398908]

246. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. [PubMed 9398894]

247. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 1996; 38:25-34. [PubMed 8598824]

248. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. [PubMed 8399892]

249. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated.) Clin Infect Dis. 1993; 17:294-5.

250. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. [IDIS 273364] [PubMed 1974027]

251. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet. 1991; 337:1614. [PubMed 1675746]

252. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.

253. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med. 1991; 115:266-9. [IDIS 284354] [PubMed 1854110]

254. Hentschel E, Brandstätter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12. [IDIS 308862] [PubMed 8419816]

255. Borody T, Andrews P, Mancuso N et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992; 339:1295. [PubMed 1349686]

256. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med. 1992; 152:726-32. [IDIS 295736] [PubMed 1558429]

257. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1135. [IDIS 373209] [PubMed 8827957]

258. Soll AH. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1136-7.

259. Bell GD. Anti-Helicobacter pylori therapy: clearance, elimination, or eradication? Lancet. 1991; 337:310-1. Letter.

260. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:473-500. [PubMed 9279507]

261. TAP Pharmaceuticals, Inc. Prevacid (lansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 1997 Aug.

262. Garnett RG. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996; 30:1425. [IDIS 376983] [PubMed 8968456]

263. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy. 1997; 17:308-26. [IDIS 383782] [PubMed 9085323]

264. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; 11:1053-7.

265. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:1434-42. [IDIS 429620] [PubMed 10364004]

266. Food and Drug Administration. Maalox total relief and Maalox liquid products: medication use errors. Rockville, MD; 2010 Feb 17. From the FDA website.

267. Food and Drug Administration. Product confusion with Maalox total relief and Maalox liquid products. Rockville, MD; 2010 Feb 17.

268. Food and Drug Administration warns about serious side effects from Maalox product mix-ups. Rockville, MD; 2010 Feb 17. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200795.htm

269. Novartis Consumer Health, East Hanover: Personal communication.

a. Food and Drug Administration. Antacid products for over-the-counter (OTC) human use. [21 FR Part 331] Fed Regist. 1990; 55:19859.

b. AHFS drug information 2004. McEvoy GK, ed. Antacids. Bethesda, MD: American Society of Health-System Pharmacists; 2004:2756-61.

c. USP DI: drug information for the health care provider. Johnson KW, ed. 24th ed. Englewood, CO: Micromedex, Inc; 2004:202-21. Antacids (oral-local).

d. American Pharmaceutical Association. Handbook of nonprescriptin drugs. 14th ed. Washington, DC: American Pharmaceutical Association; 2004:317-48.

e. American Gastroenterological Association Consensus Development Panel. Improving the management of GERD: evidence-based therapeutic strategies. Bethesda, MD: AGA Press; 2002:1-24.

f. American Pharmaceutical Association. Handbook of nonprescriptin drugs. 13th ed. Washington, DC: American Pharmaceutical Association; 2004:267-303.

Hide
(web5)